Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have earned an average recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $13.75.

Separately, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th.

Theravance Biopharma Stock Up 0.3 %

NASDAQ TBPH opened at $9.39 on Friday. The firm’s 50 day moving average is $9.32 and its 200-day moving average is $9.05. The company has a market capitalization of $464.53 million, a PE ratio of -9.30 and a beta of 0.15. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last announced its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The business had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million. As a group, sell-side analysts expect that Theravance Biopharma will post -1.09 EPS for the current year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the company’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares of the company’s stock, valued at approximately $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Aquatic Capital Management LLC bought a new stake in Theravance Biopharma during the fourth quarter worth $25,000. Quantbot Technologies LP bought a new stake in Theravance Biopharma during the third quarter worth $60,000. KLP Kapitalforvaltning AS bought a new stake in Theravance Biopharma during the fourth quarter worth $69,000. Teacher Retirement System of Texas bought a new stake in Theravance Biopharma during the fourth quarter worth $103,000. Finally, ClearAlpha Technologies LP bought a new position in shares of Theravance Biopharma in the fourth quarter valued at about $109,000. 99.10% of the stock is owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.